Abbott India dividend exceeds half-year operating cash flow

Abbott India Limited paid Rs 1,393.95 crore in dividends in the six months ended September 30, 2026, Rs 734.98 crore more than its Rs 658.97 crore net cash from operating activities; Rs 2,296.12 crore in fixed-deposit redemptions contributed to a Rs 1,159.19 crore investing inflow.

How much dividend did Abbott India pay in the first half?

Abbott India paid Rs 1,393.95 crore in dividends during the six months ended September 30, 2026, compared with Rs 1,009.34 crore in the corresponding six months of 2025. The payment rose by Rs 384.61 crore year on year and was recorded in financing activities in the unaudited cash-flow statement.

The dividend represented most of Abbott India’s Rs 1,423.05 crore net financing cash outflow for the 2026 half-year. The remaining outflows comprised Rs 19.68 crore of lease-principal payments, Rs 8.04 crore of lease-interest payments and Rs 1.38 crore of interest paid other than on leases.

Abbott India’s dividend was Rs 734.98 crore above its operating cash inflow in the 2026 half-year. In the previous-year period, the Rs 1,009.34 crore dividend exceeded Rs 521.94 crore of operating cash flow by Rs 487.40 crore, widening the gap by Rs 247.58 crore.

Did Abbott India’s operating cash flow cover the dividend?

No, Abbott India’s Rs 658.97 crore net operating cash inflow did not cover its Rs 1,393.95 crore dividend in the six months ended September 30, 2026. The operating inflow was equivalent to about 47% of the dividend payment, based on the two reported cash-flow lines.

Cash generated from operations before income-tax payments was Rs 949.22 crore, up from Rs 748.14 crore in the September 2025 half-year. Income tax paid, including tax deducted at source, rose to Rs 290.25 crore from Rs 226.20 crore, reducing the reported operating cash inflow to Rs 658.97 crore.

Profit before tax increased to Rs 1,182.68 crore from Rs 1,039.06 crore, but several working-capital changes absorbed cash. Trade receivables increased by Rs 109.39 crore, inventories increased by Rs 15.51 crore and trade payables decreased by Rs 85.52 crore; these were partly offset by a Rs 49.45 crore decrease in other assets and a Rs 12.81 crore increase in other liabilities and provisions.

The Rs 137.03 crore year-on-year increase in operating cash flow was smaller than the Rs 384.61 crore increase in dividends. Abbott India disclosed a single Pharmaceuticals segment and did not provide a segment-level cash-flow split or a specific allocation of cash sources to the dividend.

What cash movements accompanied Abbott India’s dividend payment?

Abbott India reported Rs 1,159.19 crore of net cash generated from investing activities in the September 2026 half-year, compared with Rs 548.35 crore a year earlier. The principal driver was Rs 2,296.12 crore of fixed-deposit redemptions, against Rs 1,195.99 crore invested in fixed deposits with original maturity of more than three months.

The fixed-deposit transactions produced a net redemption of Rs 1,100.13 crore in the 2026 half-year. Abbott India also received Rs 73.97 crore of deposit interest, spent Rs 15.05 crore on property, plant and equipment including intangible assets and capital work-in-progress, and received Rs 0.14 crore from asset sales.

Net investing cash flow increased by Rs 610.84 crore from the prior-year half. Redemptions rose by Rs 294.64 crore and new fixed-deposit investments rose by Rs 210.00 crore, while interest received on deposits fell by Rs 107.41 crore.

The cash-flow statement reports aggregate categories rather than earmarked funding for individual payments. It therefore shows that deposit redemptions and operating cash were available within the overall cash movements, but Abbott India does not state that a particular fixed-deposit redemption was designated to fund the dividend.

How did Abbott India’s cash position change after the payout?

Abbott India’s cash and cash equivalents increased by Rs 395.11 crore to Rs 837.44 crore at September 30, 2026, from Rs 442.33 crore at March 31, 2026. The increase reflects the combined Rs 658.97 crore operating inflow, Rs 1,159.19 crore investing inflow and Rs 1,423.05 crore financing outflow.

The balance sheet showed changes in the composition of financial assets during the same six months. Bank balances other than cash and cash equivalents declined to Rs 717.39 crore from Rs 1,812.62 crore, while current other financial assets rose to Rs 837.86 crore from Rs 131.15 crore and non-current other financial assets fell to Rs 1,642.16 crore from Rs 2,347.60 crore.

Total assets declined to Rs 5,924.91 crore at September 30, 2026, from Rs 6,501.93 crore at March 31, 2026. Total equity decreased to Rs 4,270.20 crore from Rs 4,774.19 crore, while the filing identifies the dividend as a financing outflow but does not provide a separate reconciliation between the dividend and other equity.

Abbott India reported revenue from operations of Rs 3,764.69 crore for the six months ended September 30, 2026, compared with Rs 3,495.50 crore a year earlier. Profit for the period was Rs 881.97 crore, providing an earnings measure alongside the cash-flow movements affected by tax, working capital, deposit transactions and dividends.

Conclusion

Abbott India’s September 2026 half-year cash flows show that its Rs 1,393.95 crore dividend exceeded the Rs 658.97 crore generated from operations. Net investing inflows of Rs 1,159.19 crore, led by Rs 2,296.12 crore of fixed-deposit redemptions, coincided with a Rs 395.11 crore increase in cash and cash equivalents despite the financing outflow.

The filing does not disclose a future dividend plan or identify specific fixed-deposit redemptions as dividend funding. The next results disclosure can clarify whether operating cash flow, tax payments, receivables, inventories and fixed-deposit transactions change from the September 2026 half-year levels.